News & Events
July 21, 2021
WEBINAR | How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease
When: July 21, 2021, 12 p.m. ET
Case Study: Northstar Ambulatory Assessment as an outcome assessment in Duchenne muscular dystrophy
Presenters: Varun Aggarwal, PhD, Director, Statistical and Mathematical Medicine, Quantitative Medicine; Kevin Krudys, PhD, Office of Clinical Pharmacology, FDA
RDCA-DAP team: Jeff Barrett, PhD, FCP, Senior Vice President, RDCA-DAP Lead; Alexandre Bétourné, PhD, PharmD, Scientific Director, RDCA-DAP
July 20, 2021
Digital Health Technologies Hold Key to New Parkinson’s TreatmentsGlobal stakeholders come together to collaborate with urgency to address unmet needs for Parkinson’s therapies. TUCSON, Ariz., July 20, 2021 — The use of digital health technologies across health care and drug development has accelerated. A new paper titled “Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective,” co-authored by experts across......
July 15, 2021
Launch of UNITE4TB Partnership Marks a New Era in Tuberculosis Treatment Development
To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners from 13 countries has officially launched. The 7-year, €185 million project called UNITE4TB, aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.
July 8, 2021
C-Path Announces Health Care Leader Appointment to Board of Directors
TUCSON, Ariz., July 8, 2021 — Critical Path Institute today announced the appointment of health care industry leader and active civic involvement pioneer Mara G. Aspinall, MBA, to its Board of Directors.
June 28, 2021
REQUEST FOR PROPOSAL: OMOP CDM Mapping, Training, and ConsultingC-Path’s Data Collaboration Center’s Data Science Team is seeking proposals from U.S.-based vendors to provide expertise and on-demand services related to the Observational Health Data Sciences and Informatics (OHDSI) Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for our rare disease data sharing platform, the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). We......